Abstract:Miltefosine, initially developed as an anti-tumor agent, is the newest drug for the treatment of visceral leishmaniasis. Several laboratories have shown that this ether-lipid analogue is also toxic against different forms of T. cruzi, but its mechanism(s) of action is(are) still unclear. In leukemic cells, Miltefosine seems to interfere with cellular signal transduction pathways by inhibition of protein kinase C (PKC) and Na + , K + -ATPase. In order to verify if Miltefosine is able to act in a similar way on … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.